Korsana Biosciences vs Neuphoria Therapeutics
KRSA and NEUP side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KRSA and NEUP compare
Korsana Biosciences scores higher on the StockData Score (8 against 5 for Neuphoria Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KRSA | NEUP |
|---|---|---|
| Size and price | ||
| Market cap | $1.4B | – |
| Share price | $31.65 | $2.55 |
| Change, 1 year | 218% | −48.0% |
| Change, 5 years | −90.3% | – |
| Beta (5Y) | 1.41 | 0.86 |
| Employees | 1 | 7 |
| StockData Score | ||
| Total score | 8 (better) | 5 |
| Valuation score | 0 | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 3.7× | – |
| Growth | ||
| Revenue growth, 5Y average | −2.0% | – |
| Profitability | ||
| Return on equity | −31.8% (better) | −61.7% |
| Return on invested capital | – | −273% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 10.42 | 27.85 (better) |
| Altman Z-score | 19.65 | – |
| Piotroski F-score | 5 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 1.6% | 36.8% |
| Held by insiders | 46.5% | – |
| Insider net buying, 12 months | – | $0 |
| Short interest, % of float | 0.69% | – |
Go deeper
- KRSA stock overview
- KRSA income statement
- KRSA valuation and score
- NEUP stock overview
- NEUP income statement
- NEUP valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.